Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Penson

Showing results (281-290 of 570) with videos related to

Pageof 57
Sort By:
The Urologic Clinics of North America|May 9, 2003
The physical burden of prostate cancerDavid F Penson, Mark S Litwin
Pharmacoeconomics|April 4, 2007
Pharmacoeconomics of available treatment options for metastatic prostate cancerSteven B Zeliadt, David F Penson
BJU International|January 17, 2024
What is cancer? A focus on Grade Group 1 prostate cancerRuchika Talwar, Olutiwa Akinsola, David F Penson
Clinical Advances in Hematology & Oncology : H&O|February 25, 2012
The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancerEric J Small, David F Penson, Oliver Sartor
The Journal of Urology|April 20, 2010
Health related quality of life for men treated for localized prostate cancer with long-term followupGeorge J Huang, Natalia Sadetsky, David F Penson
BJU International|May 20, 2011
Pelvic organ prolapse (POP) surgery: the evidence for the repairsAlex Gomelsky, David F Penson, Roger R Dmochowski
Journal of Oncology Practice|April 2, 2015
Prostate cancer survivorship care guidelines: American Society of Clinical Oncology practice guideline endorsementMatthew J Resnick, Christina Lacchetti, David F Penson, et al.
The Journal of Urology|September 18, 2010
Health care reform 2010: a fresh view on tort reformC J Stimson, Roger Dmochowski, David F Penson
The Journal of Urology|April 11, 2003
Health related quality of life in men with prostate cancerDavid F Penson, Mark S Litwin, Neil K Aaronson
Urology|August 11, 2004
Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literatureMarian L Neuhouser, Alan R Kristal, David F Penson
Pageof 57

Showing results (281-290 of 570) with videos related to

Sort By:
Pageof 57
The Urologic Clinics of North America|May 9, 2003
The physical burden of prostate cancerDavid F Penson, Mark S Litwin
Pharmacoeconomics|April 4, 2007
Pharmacoeconomics of available treatment options for metastatic prostate cancerSteven B Zeliadt, David F Penson
BJU International|January 17, 2024
What is cancer? A focus on Grade Group 1 prostate cancerRuchika Talwar, Olutiwa Akinsola, David F Penson
Clinical Advances in Hematology & Oncology : H&O|February 25, 2012
The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancerEric J Small, David F Penson, Oliver Sartor
The Journal of Urology|April 20, 2010
Health related quality of life for men treated for localized prostate cancer with long-term followupGeorge J Huang, Natalia Sadetsky, David F Penson
BJU International|May 20, 2011
Pelvic organ prolapse (POP) surgery: the evidence for the repairsAlex Gomelsky, David F Penson, Roger R Dmochowski
Journal of Oncology Practice|April 2, 2015
Prostate cancer survivorship care guidelines: American Society of Clinical Oncology practice guideline endorsementMatthew J Resnick, Christina Lacchetti, David F Penson, et al.
The Journal of Urology|September 18, 2010
Health care reform 2010: a fresh view on tort reformC J Stimson, Roger Dmochowski, David F Penson
The Journal of Urology|April 11, 2003
Health related quality of life in men with prostate cancerDavid F Penson, Mark S Litwin, Neil K Aaronson
Urology|August 11, 2004
Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literatureMarian L Neuhouser, Alan R Kristal, David F Penson
Pageof 57